paroxetine has been researched along with Cognition Disorders in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Betti, L; Bonuccelli, U; Ceravolo, R; Giannaccini, G; Kiferle, L; Mazzucchi, S; Palego, L; Palermo, G; Unti, E | 1 |
| Belzung, C; Griebel, G; Philbert, J | 1 |
| Burke, A; Gorlyn, M; Grunebaum, M; Keilp, J; Mann, JJ; Oquendo, M | 1 |
| Belcher, DC; Dowben, JS; Keltner, NL; Kowalski, PC | 1 |
| Baker, R; Jackson, D | 1 |
| Bouzinova, EV; Finsen, B; Hasselstrøm, JB; Olesen, LØ; Severino, M; Sivasaravanaparan, M; Wiborg, O | 1 |
| Ellison, JM | 1 |
| Dew, MA; Ginsberg, J; Houck, PR; Ma, Y; Mulsant, BH; Pollock, BG; Reynolds, CF; Smith, GS | 1 |
| Bertoletti, E; Chilovi, BV; Conti, M; Padovani, A; Rozzini, L; Trabucchi, M; Zanetti, M | 1 |
| Bienfait, KL; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M; Tröster, A | 1 |
| Belzung, C; Griebel, G; Palme, R; Philbert, J; Pichat, P | 1 |
| Ferguson, JM; Schwartz, GE; Wesnes, KA | 1 |
| Reynolds, CF | 1 |
| Adeoye, OM; Begley, AE; Ferrell, RE; Kirshner, MA; Mulsant, BH; Pollock, BG; Reynolds, CF; Seligman, K | 1 |
| Houck, PR; Koru-Sengul, T; Mazumdar, S; Mulsant, BH; Pollock, BG; Reynolds, CF; Tang, G | 1 |
| Basinski, J; Butters, MA; Dew, MA; Driscoll, HC; Houck, PR; Mazumdar, S; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Schlernitzauer, MA; Stack, JA | 1 |
| Bigaillon, C; Burnat, P; Ceppa, F; El Jahiri, Y; Garcia, C; Hejl-Garcia, C; Mayaudon, H | 1 |
| Alexander, T; Ances, BM; Ellis, RJ; Letendre, SL | 1 |
| Amsterdam, JD; Beck, AT; Bhar, SS; DeRubeis, RJ; Gallop, R; Gelfand, LA; Hollon, SD; Schmid, SP; Shelton, RC | 1 |
| Guardia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, J; Herrera-Guzmán, D; Herrera-Guzmán, I; Lira-Mandujano, J; Montoya-Pérez, K | 1 |
| Böhmer, F; Geretsegger, C; Ludwig, M | 1 |
| Baldassarre, P; Loriedo, C; Paolillo, A; Raccah, R; Vella, G | 1 |
| Butters, MA; Mulsant, BH; Nebes, RD; Pollock, BG; Reynolds, CF; Zmuda, MD | 1 |
| Becker, JT; Butters, MA; Mulsant, BH; Nebes, RD; Pollock, BG; Reynolds, CF; Zmuda, MD | 1 |
3 review(s) available for paroxetine and Cognition Disorders
| Article | Year |
|---|---|
Biological Perspectives: Huntington's Disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Dementia; Humans; Huntington Disease; Magnetic Resonance Imaging; Male; Memory, Short-Term; Mood Disorders; Olanzapine; Paroxetine | 2015 |
Paroxetine treatment of depression in late life.
Topics: Aged; Antidepressive Agents, Second-Generation; Cognition Disorders; Delayed-Action Preparations; Depressive Disorder; Humans; Paroxetine; Suicide Prevention | 2003 |
Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders.
Topics: Antiretroviral Therapy, Highly Active; Brain; Citalopram; Cognition Disorders; HIV Infections; Humans; Lithium Carbonate; Mental Disorders; Paroxetine; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Valproic Acid | 2008 |
9 trial(s) available for paroxetine and Cognition Disorders
| Article | Year |
|---|---|
Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Suicidal Ideation; Suicide, Attempted; Treatment Outcome | 2015 |
Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study.
Topics: Aged; Brain; Cognition Disorders; Depressive Disorder, Major; Glucose; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Paroxetine; Positron-Emission Tomography; Selective Serotonin Reuptake Inhibitors; Sleep Deprivation | 2009 |
The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
Topics: Adult; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Parkinson Disease; Paroxetine; Time Factors; Treatment Outcome | 2010 |
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Paroxetine; Placebos; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition Disorders; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Paroxetine; Reference Values; Research Design; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2004 |
Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy.
Topics: Adult; Cognition Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2008 |
Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Geriatric Assessment; Humans; Male; Middle Aged; Neuropsychological Tests; Paroxetine; Personality Inventory; Social Behavior; Treatment Outcome | 1994 |
Cognitive effects of paroxetine in older depressed patients.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Analysis of Variance; Cognition; Cognition Disorders; Depressive Disorder; Hospitalization; Humans; Middle Aged; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Wechsler Scales | 1999 |
Changes in cognitive functioning following treatment of late-life depression.
Topics: Aged; Antidepressive Agents; Cognition Disorders; Comorbidity; Dementia; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome | 2000 |
12 other study(ies) available for paroxetine and Cognition Disorders
| Article | Year |
|---|---|
Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms.
Topics: Aged; Aged, 80 and over; Anger; Blood Platelets; Brain-Derived Neurotrophic Factor; Cognition Disorders; Female; Humans; Huntington Disease; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Paroxetine; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Social Perception; Voice | 2018 |
The CRF₁ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine.
Topics: Animals; Behavior, Animal; Cognition Disorders; Cycloserine; Electroshock; Hippocampus; Hydrocarbons, Halogenated; Male; Mice; Paroxetine; Receptors, Corticotropin-Releasing Hormone; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Thiazines; Time Factors | 2013 |
New models for describing outliers in meta-analysis.
Topics: Algorithms; Cognition Disorders; Cytidine Diphosphate Choline; Dental Caries; Fluorides; Humans; Hypercholesterolemia; Meta-Analysis as Topic; Models, Statistical; Monte Carlo Method; Paroxetine; Placebos; Pravastatin; Regression Analysis; Research Design; Software; Statistics as Topic; Toothpastes | 2016 |
Behavioural Phenotyping of APPswe/PS1δE9 Mice: Age-Rrelated Changes and Effect of Long-Term Paroxetine Treatment.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorders; Disease Models, Animal; Male; Maze Learning; Memory Disorders; Mice; Mice, Transgenic; Paroxetine; Presenilin-1; Social Behavior | 2016 |
A 60-year-old woman with mild memory impairment: review of mild cognitive impairment.
Topics: Aging; Alzheimer Disease; Cognition; Cognition Disorders; Counseling; Diagnosis, Differential; Diet; Female; Humans; Life Style; Magnetic Resonance Imaging; Memory Disorders; Middle Aged; Neurotransmitter Agents; Paroxetine; Positron-Emission Tomography; Psychotropic Drugs; Risk Factors | 2008 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Movement Disorders; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2010 |
The CRF₁ receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis.
Topics: Animals; Cognition Disorders; Corticosterone; Dexamethasone; Electroshock; Feces; Hydrocarbons, Halogenated; Hypothalamo-Hypophyseal System; Male; Mice; Paroxetine; Pituitary-Adrenal System; Receptors, Corticotropin-Releasing Hormone; Recognition, Psychology; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Thiazines | 2012 |
alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics.
Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition Disorders; Cost of Illness; Depressive Disorder, Major; Double-Blind Method; Female; Gene Expression; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Orosomucoid; Paroxetine; Severity of Illness Index; Surveys and Questionnaires | 2003 |
Late-onset major depression: clinical and treatment-response variability.
Topics: Activities of Daily Living; Age of Onset; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Cognition Disorders; Depressive Disorder, Major; Female; Humans; Male; Neuropsychological Tests; Paroxetine; Prognosis; Psychiatric Status Rating Scales; Recurrence; Time Factors; Treatment Outcome | 2005 |
[Inappropriate ADH secretion-induced hyponatremia and associated with paroxetine use].
Topics: Cognition Disorders; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2007 |
Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Brief Psychiatric Rating Scale; Bupropion; Cognition Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Neuropsychological Tests; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2008 |
Successful paroxetine treatment of major depression in an adult form of metachromatic leukodystrophy with cognitive disturbances.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognition Disorders; Depressive Disorder; Female; Humans; Leukodystrophy, Metachromatic; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1998 |